<p><strong>Females</strong>: Pazopanib can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should be advised to use effective contraception during treatment and for at least 2 weeks after the last dose of Pazopanib.<br />
<br />
<strong>Males</strong>: To avoid potential drug exposure to pregnant partners and female partners of reproductive potential, male patients (including those who have had vasectomies) with female partners of reproductive potential should be advised to use condoms during treatment with Pazopanib and for at least 2 weeks after the last dose.<br />
<br />
<strong>Pediatric Use</strong>: The safety and effectiveness of Pazopanib&nbsp;in pediatric patients have not been established.</p>